These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 24374138)
1. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. Matsuda S; Tam T; Singh RP; Kaiser PK; Petkovsek D; Carneiro G; Zanella MT; Ehlers JP J Diabetes Complications; 2014; 28(2):166-70. PubMed ID: 24374138 [TBL] [Abstract][Full Text] [Related]
2. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME; Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322 [TBL] [Abstract][Full Text] [Related]
3. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578 [TBL] [Abstract][Full Text] [Related]
4. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723 [TBL] [Abstract][Full Text] [Related]
5. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366 [TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Kim M; Lee P; Kim Y; Yu SY; Kwak HW Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A Retina; 2006; 26(9):999-1005. PubMed ID: 17151486 [TBL] [Abstract][Full Text] [Related]
8. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710 [TBL] [Abstract][Full Text] [Related]
9. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844 [TBL] [Abstract][Full Text] [Related]